<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611572</url>
  </required_header>
  <id_info>
    <org_study_id>0508000517</org_study_id>
    <nct_id>NCT00611572</nct_id>
  </id_info>
  <brief_title>GABA-glutamate Interactions and Psychosis</brief_title>
  <official_title>Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism&#xD;
      and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by&#xD;
      ERPs (event-related potentials) in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P300 as an ERP measure</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMN (Mismatch Negativity)</measure>
    <time_frame>prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active iomazenil and ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo iomazenil and ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iomazenil</intervention_name>
    <description>Given as IV infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iomazenil</intervention_name>
    <description>saline IV infusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ages of 21-45 years from all ethnic backgrounds.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.&#xD;
&#xD;
          -  A history of significant medical/neurological disease such as cardiac, thyroid, renal,&#xD;
             hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital&#xD;
             signs, physical examination and laboratory work-up (CBC with differential, SMA-7,&#xD;
             LFTs, TFTs, UA, Utox).&#xD;
&#xD;
          -  History of abnormal EEG.&#xD;
&#xD;
          -  History of severe allergies or multiple adverse drug reactions.&#xD;
&#xD;
          -  Any medication that could interfere with either the safety of the study and/or the&#xD;
             outcome measures.&#xD;
&#xD;
          -  Any other conditions which in the opinion of the investigator would preclude&#xD;
             participation in the study.&#xD;
&#xD;
          -  History of major psychiatric disorder in first degree relatives.&#xD;
&#xD;
          -  Current substance abuse/dependency determined by urine toxicology.&#xD;
&#xD;
          -  Treatment with medications with CNS effects.&#xD;
&#xD;
          -  Treatment with benzodiazepines within one week prior to testing.&#xD;
&#xD;
          -  Current treatment with medications with psychotropic effects.&#xD;
&#xD;
          -  Education &lt; 10th grade.&#xD;
&#xD;
          -  IQ &lt; 70, MR.&#xD;
&#xD;
          -  Non-English speaking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohini Ranganathan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine, Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VHA Connecticut</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GABA</keyword>
  <keyword>glutamate</keyword>
  <keyword>NMDA</keyword>
  <keyword>P300</keyword>
  <keyword>MMN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

